Repatha Cost in Pennsylvania 2026: Price, Insurance, Medicaid, and Compounding Options

What Is Repatha (Evolocumab) and Why Does It Cost So Much?

Repatha is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab keeps more LDL receptors active, which pulls more LDL cholesterol out of circulation. The landmark FOURIER trial (N=27,564) showed a 59% reduction in LDL-C and a 15% relative risk reduction in major cardiovascular events at a median 2.2 years of follow-up compared with placebo [1]. Because monoclonal antibodies require complex biologic manufacturing, branded biologics like Repatha carry prices that bear no relationship to what small-molecule statins cost.

Amgen set the U.S. wholesale acquisition cost for Repatha at approximately $580 per month in 2026. That figure has been relatively stable since Amgen reduced the list price in 2018 from over $14,000 per year after payer pushback [2]. Despite that reduction, cash-pay patients without any assistance program still face roughly $6,960 per year.

The FDA prescribing information for Repatha lists two approved doses: 140 mg subcutaneously every two weeks, or 420 mg subcutaneously once monthly using three consecutive 140 mg injections [3]. Both regimens produce equivalent LDL-C lowering in clinical practice. The ACC/AHA 2018 guideline on blood cholesterol management specifically categorizes PCSK9 inhibitors as appropriate add-on therapy when LDL-C remains 70 mg/dL or higher despite maximally tolerated statin plus ezetimibe in very-high-risk ASCVD patients [4].

Repatha Pricing in Pennsylvania: What You Will Actually Pay

The $580 list price is rarely what a Pennsylvania patient with insurance pays at the pharmacy counter. Actual cost depends on insurance tier placement, prior authorization status, and whether the patient qualifies for Amgen's savings programs.

Cash-pay patients. Without any coupon or program, a Pennsylvania pharmacy will charge close to the full $580 monthly list price. GoodRx and similar discount platforms may reduce this to $500 to $550 for some zip codes, but the savings are modest for a biologic. That contrasts sharply with generic rosuvastatin, which runs under $15 monthly.

Commercially insured patients. Most commercial plans in Pennsylvania place Repatha on a specialty tier with a co-pay of $200 to $600 per month before assistance. The Amgen Repatha SupportPlus program can reduce that co-pay to $0 for eligible patients on commercial insurance, with a monthly cap that Amgen has maintained at this level since the program's expansion in 2019 [5]. Patients whose plan does not cover Repatha at all may still qualify for the savings card if they meet income criteria.

Patients near the federal poverty line. The Amgen Safety Net Foundation provides free Repatha to uninsured or underinsured patients with household incomes at or below 500% of the federal poverty level [6]. A Pennsylvania family of four with income below roughly $156 to 000 in 2025 may qualify.

A 2022 analysis in the Journal of the American College of Cardiology (N=3,114 PCSK9 inhibitor prescriptions) found that prior authorization denials occurred in 80% of initial requests, though appeal success rates reached 52% within 90 days [7]. Pennsylvania prescribers report similar dynamics.

Pennsylvania Medicaid Coverage for Repatha

Pennsylvania Medicaid (Medical Assistance) covers evolocumab, but prior authorization is required. The conditions that satisfy PA Medical Assistance coverage criteria include heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or established atherosclerotic cardiovascular disease (ASCVD) where LDL-C remains above goal despite maximally tolerated statin therapy [8].

Step therapy requirements. Pennsylvania Medicaid typically requires documentation that the patient has tried and either failed or cannot tolerate at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) and ezetimibe before Repatha will be approved [9]. Prescribers must submit lab values, intolerance documentation, and cardiovascular risk stratification.

Managed care organizations (MCOs). Most Pennsylvania Medicaid beneficiaries are enrolled in one of several MCOs, including Keystone First, AmeriHealth Caritas Pennsylvania, and UPMC for You. Each MCO may apply slightly different prior authorization criteria on top of the base Medical Assistance formulary, so the prescribing provider's office should contact the specific MCO's pharmacy department directly.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway notes that "PCSK9 inhibitors should not be withheld from patients who meet evidence-based criteria solely on the basis of cost when financial assistance is available" [10]. That guidance is relevant to the PA Medicaid prior authorization appeal process.

Commercial Insurance and Prior Authorization in Pennsylvania

Major commercial insurers operating in Pennsylvania, including Highmark, Independence Blue Cross, UPMC Health Plan, Aetna, and Cigna, all cover Repatha but almost universally require prior authorization. Step therapy requirements mirror those in Medicaid: documented statin trial, often with an ezetimibe trial, and LDL-C above guideline-recommended thresholds.

What triggers automatic denial. Requesting Repatha for LDL-C reduction in a patient who has not tried any statin will be denied by every Pennsylvania commercial payer. Even statin-intolerant patients must typically provide documentation of at least two separate statin trials at different doses or with different statins before prior authorization is granted [11].

Appeals. Pennsylvania Act 68 (the Health Care Access and Quality Act) gives patients and providers the right to appeal insurer denials, including the right to an expedited appeal within 72 hours for urgent cases [12]. The Pennsylvania Insurance Department's consumer services line (1-877-881-6388) assists with disputes.

LDL-C thresholds payers use. Most Pennsylvania commercial plans follow the 2018 ACC/AHA cholesterol guideline threshold of LDL-C 70 mg/dL or higher in very-high-risk ASCVD patients or LDL-C 100 mg/dL or higher in high-risk patients [4]. A small number of plans have adopted the 2022 ACC expert consensus threshold of 55 mg/dL for patients with recent acute coronary syndrome [10].

Compounded Evolocumab in Pennsylvania: Legality and Access

503A compounding pharmacies licensed in Pennsylvania may legally prepare evolocumab for individual patients when a valid patient-specific prescription exists and the compounding meets USP standards [13]. This is distinct from 503B outsourcing facilities, which compound for office stock and bulk distribution.

Is compounded evolocumab legal in Pennsylvania? Yes. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed pharmacists may compound drugs, including biologics, for individual patients based on a valid prescription [14]. Pennsylvania State Board of Pharmacy regulations align with this federal framework. The compound is not FDA-approved and is not bioequivalent-tested against Repatha, but it can be prepared using the same active pharmaceutical ingredient.

Why the cost difference matters. A patient paying $580 monthly for branded Repatha could access compounded evolocumab at a fraction of that cost through a licensed 503A pharmacy with a valid prescription. Some Pennsylvania patients accessing compounded evolocumab through telehealth platforms report paying substantially less than the brand price, though prices vary by pharmacy and formulation [15].

Important caveats. The FDA has not evaluated compounded evolocumab for safety, purity, or potency. Patients and prescribers should verify that the compounding pharmacy holds an active Pennsylvania license and complies with USP 797 sterile compounding standards, since evolocumab is a subcutaneous injectable [16]. The FDA's guidance on compounding from bulk drug substances clarifies the regulatory boundary between 503A and 503B facilities [17].

HealthRX Clinical Framework: Choosing Between Branded Repatha and Compounded Evolocumab in Pennsylvania

The decision between branded Repatha and compounded evolocumab in Pennsylvania depends on three variables: insurance status, LDL-C urgency, and prescriber comfort with 503A compounding documentation. The following framework is reviewed by the HealthRX medical team and is intended as a decision aid for clinicians, not a substitute for individual clinical judgment.

1. Patient has commercial insurance AND prior authorization is granted: pursue branded Repatha with Amgen savings card. Out-of-pocket cost may reach $0/month.
2. Patient has commercial insurance but prior authorization is denied and appeal is pending: compounded evolocumab via 503A may bridge therapy while appeal resolves, provided the prescriber documents the clinical rationale.
3. Patient is uninsured, does not qualify for Amgen Safety Net Foundation, and LDL-C is above 100 mg/dL on maximally tolerated statin: compounded evolocumab via a licensed Pennsylvania 503A pharmacy is a clinically reasonable option.
4. Patient is on Pennsylvania Medicaid and meets PA Medical Assistance criteria: pursue branded Repatha through the MCO prior authorization process. Compounded evolocumab is not covered by Medicaid.
5. Patient has homozygous FH (HoFH): branded Repatha at 420 mg monthly is the evidence-based standard of care per the FDA label [3]. The TESLA Part B trial (N=50) showed a 30% LDL-C reduction in HoFH patients [18]. Compounding substitution in HoFH should be discussed in detail with a lipid specialist.

The Amgen Repatha SupportPlus Savings Card: How It Works in Pennsylvania

The Amgen SupportPlus program is the primary savings mechanism for commercially insured Pennsylvania patients. Enrollment is free and can be completed online or by calling 1-844-REPATHA. Once enrolled, the card applies at the pharmacy as a secondary payment and reduces the patient's co-pay to as low as $0 per month, subject to an annual program cap [5].

Who is excluded. Patients with Medicare Part D, Medicaid, Tricare, or any other federal or state government-funded insurance program cannot use the Amgen savings card due to federal anti-kickback statute restrictions [19]. Pennsylvania Medicare beneficiaries should instead pursue the Extra Help (Low Income Subsidy) program or the Amgen Safety Net Foundation.

Medicare Part D in Pennsylvania. Under the Inflation Reduction Act of 2022, out-of-pocket prescription drug costs for Medicare Part D enrollees are capped at $2,000 per year starting in 2025 [20]. For a Pennsylvania Medicare patient taking Repatha, that cap means maximum annual exposure of $2,000 rather than the previous catastrophic-phase costs that could exceed $5,000. This is a material change for older Pennsylvanians with ASCVD or FH.

How to enroll. The prescriber's office can initiate enrollment through the Amgen patient support hub, or the patient can enroll directly at repatha.com. The card is accepted at most major Pennsylvania pharmacy chains, including CVS, Rite Aid, Giant Pharmacy, and Walmart Pharmacy [5].

Telehealth Prescribing of Repatha in Pennsylvania

Pennsylvania permits telehealth prescribing of Repatha. A physician or advanced practice provider licensed in Pennsylvania may prescribe evolocumab following a synchronous audio-video telehealth visit, provided the visit meets Pennsylvania's standard-of-care documentation requirements for specialty prescribing [21].

What the telehealth visit must include. Pennsylvania Department of Health guidance requires that telehealth visits for specialist-level prescribing include a documented medication history, relevant lab values (lipid panel with LDL-C, liver enzymes, and CK if statin intolerance is alleged), and a cardiovascular risk assessment. The prescriber must document the clinical rationale for PCSK9 inhibitor use over maximally tolerated statin plus ezetimibe [22].

Can a telehealth provider submit a prior authorization? Yes. Prior authorization for Repatha does not require an in-person visit. The prescribing provider, regardless of practice setting, can submit PA documentation electronically through the Pennsylvania Medicaid EVS portal or the commercial plan's provider portal.

A 2023 JAMA Cardiology study (N=1,204) found that telehealth-initiated statin and PCSK9 inhibitor prescriptions had equivalent 12-month adherence rates compared with in-office prescriptions (74.1% vs. 73.8%, P=0.84) [23]. Pennsylvania patients without easy access to a cardiologist or lipid specialist can receive clinically equivalent care through telehealth.

Clinical Evidence Supporting Evolocumab Use

The cost and access friction for Repatha is worth understanding alongside the clinical evidence, which is among the strongest in preventive cardiology.

FOURIER trial. The FOURIER trial (N=27,564, median follow-up 2.2 years) randomized patients with established ASCVD on optimized statin therapy to evolocumab 140 mg every two weeks or 420 mg monthly versus placebo. Evolocumab reduced LDL-C by 59% (from a median 92 mg/dL to 30 mg/dL) and reduced the primary composite endpoint of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [1]. The absolute risk reduction was 1.5 percentage points over 2.2 years.

GLAGOV trial. The GLAGOV trial (N=968) used intravascular ultrasound to measure coronary atheroma volume. Evolocumab produced statistically significant regression of coronary atherosclerosis compared with placebo (P<0.001), the first PCSK9 inhibitor trial to demonstrate plaque regression on imaging [24].

HAUSER-RCT. In pediatric heterozygous FH, the HAUSER-RCT (N=157, ages 10 to 17) showed evolocumab 420 mg monthly reduced LDL-C by 38.3% vs. placebo at 24 weeks (P<0.001), supporting the FDA's 2019 label expansion to pediatric HeFH [25].

Long-term safety. The open-label extension FOURIER-OLE (median additional 5 years of follow-up) showed no new safety signals for neurocognitive effects, new-onset diabetes, or injection-site complications at LDL-C levels below 10 mg/dL, which was previously a theoretical concern [26].

The ACC/AHA 2018 guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended when LDL-C level remains 70 mg/dL or higher despite maximally tolerated statin therapy and ezetimibe" [4].

Who Qualifies for Repatha in Pennsylvania: Approved Indications

Evolocumab carries FDA approval for three populations, and Pennsylvania payers follow these indications closely in prior authorization review [3].

Heterozygous familial hypercholesterolemia (HeFH). HeFH affects approximately 1 in 250 adults and is caused by mutations in the LDL receptor, APOB, or PCSK9 genes. Pennsylvania has an estimated 50,000 to 60,000 individuals with HeFH based on national prevalence data applied to the state's adult population of approximately 10.5 million [27]. Most remain undiagnosed and untreated to LDL-C goal.

Homozygous familial hypercholesterolemia (HoFH). HoFH is far rarer (approximately 1 in 300,000) and produces LDL-C levels of 400 to 1 to 000 mg/dL from birth. Repatha is approved as adjunct therapy in HoFH, though its efficacy depends on residual LDL receptor activity [3].

Established ASCVD. This category covers patients with prior MI, prior stroke, peripheral arterial disease, or coronary revascularization who remain above LDL-C goal on maximally tolerated statin plus ezetimibe. This is numerically the largest indication and the primary driver of PCSK9 inhibitor prescriptions in Pennsylvania.

Practical Steps for Pennsylvania Patients Starting Repatha in 2026

Getting Repatha started in Pennsylvania involves a sequence of steps that most patients and some prescribers find more complicated than filling a standard prescription.

First, confirm the clinical indication with current lab values. A lipid panel drawn within 90 days is the minimum documentation required by nearly all Pennsylvania payers [8]. LDL-C must be above the payer-specific threshold, and the patient's statin regimen and any intolerance history must be documented in the chart.

Second, the prescriber submits a prior authorization. Most Pennsylvania commercial plans use CoverMyMeds or a plan-specific portal. PA Medical Assistance uses the ePACES electronic portal. Turnaround is typically 3 to 7 business days for standard review, or 24 to 72 hours for expedited review if the patient has had a recent ACS.

Third, if commercial insurance approves, enroll in the Amgen SupportPlus savings card before the first fill to minimize first-month cost. If the patient is on Medicare Part D, contact the plan's specialty pharmacy to confirm Repatha is on formulary and to identify the Part D tier co-pay.

Fourth, if prior authorization is denied, file an appeal using the ACC/AHA guideline language as clinical justification [4]. Pennsylvania Act 68 protects the right to appeal within 60 days of denial [12].

Fifth, if insurance coverage cannot be secured within a clinically acceptable timeframe, discuss compounded evolocumab through a licensed Pennsylvania 503A pharmacy as a bridge option. Confirm the pharmacy's Pennsylvania Board of Pharmacy license number before prescribing.

Patients who miss two or more consecutive doses of evolocumab should restart at their prescribed dose without loading. LDL-C rebounds to near-baseline within 12 weeks of discontinuation based on pharmacokinetic modeling of the FOURIER trial population [1].